• Fig A shows a schematic representation

  2024-12-26

  

  Fig. 2A shows a schematic representation of histological results according to the Franklin and Paxinos Mouse Brain Atlas (2001). The black circles represent the sites of drug infusion that were on-target within the amygdala. Gray circles represent the animals that had infusion locations outside the

• Compound was docked into the active site of Aurora B

  2024-12-26

  

  Compound was docked into the active site of Aurora B kinase using Tripos sybyl-X ver. 2.1.1. The crystal structure of human Aurora B kinase cocrystallized with its potent inhibitor VX-680 was used for the docking analysis (PDB ID: ). The most likely binding conformations were selected based on the

• br Acknowledgment br Introduction The yeast Cdc ATPase and

  2024-12-26

  

  Acknowledgment Introduction The yeast Cdc48 ATPase and its metazoan ortholog p97 (or VCP) are critical components of many ubiquitin-dependent cellular pathways that require the segregation of individual proteins from binding partners or membranes (for review, see Buchberger, 2013, Meyer and We

• Aminoglutethimide first generation aromatase inhibitor has b

  2024-12-26

  

  Aminoglutethimide, first generation aromatase inhibitor, has been tried as an antiepileptic drug in combination with other standard drugs (Aguilar et al., 1961). Letrozole is a third generation reversible non-steroidal aromatase inhibitor, approved by US-FDA, for the treatment of postmenopausal wome

• Introduction Lipoxygenases LOXs are key enzymes that catalyz

  2024-12-25

  

  Introduction Lipoxygenases (LOXs) are key enzymes that catalyze the polyunsaturated fatty acids (PUFAs) such as arachidic CNO in vivo studies (AA), linoleic acid (LA) and others unsaturated fatty acids (Brash, 1999). LOXs are expressed in immune, neural, epithelial, tumor cells and other cells (Cl

• br Discussion The present understanding is that patients suf

  2024-12-25

  

  Discussion The present understanding is that patients suffering from AD are at a higher risk for epilepsy than individuals without AD [[1], [2]]. The clinical diagnostic accuracy of AD has improved significantly during the last decades. However, most of the epidemiological studies on these two of

• br Experimental section br Introduction

  2024-12-25

  

  Experimental section Introduction Microglia were discovered as a novel cell population in BHQ in 1933 by a Spanish physician and histologist Pío del Río-Hortega [1]. In the eye, scientists used Hortega's staining technique to label the microglia in the retinal outer plexiform layer (OPL) in m

• br Introduction Our ability to see our

  2024-12-25

  

  Introduction Our ability to see our surrounding relies directly on the integrity of the anatomical structures composing our eyes. One of these key components is the cornea, consisting of the outer layer of the eye. Its transparency is crucial for light transmission to the retina and allows proper

• The direction of research then

  2024-12-25

  

  The direction of research then turned to investigating the long-term effects of adiponectin on insulin resistance. Adiponectin transgenic mice showed a reduction in insulin resistance and diabetes [5,6], while adiponectin-deficient mice showed mild insulin resistance with glucose intolerance, as wel

• br Conflict of Interest br Transparency

  2024-12-25

  

  Conflict of Interest Transparency Document Introduction Mitoxantrone (MXT) is an androstenedione chemotherapeutic agent that is used to treat acute nonlymphocytic leukemia, acute lymphoblastic leukemia, prostate cancer, metastatic breast cancer, and non-Hodgkin’s lymphoma [13], [14]. It is

• Oxaliplatin While A Rs communicate mainly with the D R

  2024-12-25

  

  While A1Rs communicate mainly with the D1R subtype [36], A2AR and D2R interaction occurs mainly in basal ganglia. D2Rs colocalizes with A2ARs in this Oxaliplatin area where they are preferentially localized postsynaptically in the soma and dendrites of GABAergic striatopallidal neurons [69]. This i

• br Introduction Adenosine deaminase ADA which can catalyze t

  2024-12-25

  

  Introduction Adenosine deaminase (ADA), which can catalyze the conversion of AD to inosine by removing an amino group, is a key hydrolytic enzyme of purine metabolism (Conway and Cooke, 1939), and plays an important role in an amount of diseases. For example, an increase of ADA activity in serum

• Our initial approach to identify

  2024-12-25

  

  Our initial approach to identify hits was two-pronged and included a high-throughput screening (HTS) campaign of the OSI bcl-2 family library as well as a virtual screening (VS) campaign, utilizing a publically available crystal structure of ACK1 (PDB code: ). A tolerance for protein flexibility wa

• Fig A shows a schematic representation

  2024-12-25

  

  Fig. 2A shows a schematic representation of histological results according to the Franklin and Paxinos Mouse Brain Atlas (2001). The black circles represent the sites of drug infusion that were on-target within the amygdala. Gray circles represent the animals that had infusion locations outside the

• Consistent with the observation that mutations in

  2024-12-25

  

  Consistent with the observation that mutations in the redox-partner binding site of P450c17 that reverse charge from basic to acidic (R347H, R358Q) cause 17,20-lyase deficiency (Geller et al, 1997, Geller et al, 1999), at least one POR mutation that changes a residue in the FMN domain from neutral t

14597 records 46/974 page Previous Next First page 上5页 4647484950 下5页 Last page